BGHL (EUR): NAV(s)
December 03, 2018 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
GC Rieber Shipping: Publication of prospectus and commencement of the subscription period
December 03, 2018 01:30 ET
|
GC Rieber Shipping
Stock Exchange NoticeDate: 3 December 2018 GC Rieber Shipping ASA: Publication of prospectus and commencement of the subscription period NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY,...
Nidec Announces the Status of Own Share Repurchase
December 03, 2018 01:30 ET
|
Nidec Corporation
KYOTO, Japan, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nidec Corporation (TSE: 6594; OTC US: NJDCY) (the “Company”) today announced the status of the Company’s own share repurchase under its ongoing...
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
December 03, 2018 01:15 ET
|
Novartis Pharma AG
The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative...
Media Release | MCH Group | Forecast for 2018
December 03, 2018 01:15 ET
|
MCH Group Ltd.
MCH Group updates its forecast for 2018 The MCH Group has updated its projection for the 2018 financial result. It expects a negative result prior to special measures of at least CHF 14 million....
Global Therapeutic Drug Monitoring Market Will Reach USD 1.7 Billion By 2024: Zion Market Research
December 03, 2018 01:11 ET
|
Zion Market Research
New York, NY, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Therapeutic Drug Monitoring Market by Product (Equipment and Consumables), by Drug Class...
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
December 03, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II...
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
December 03, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II...
Telenor: 7 tech trends that will shape 2019
December 03, 2018 01:00 ET
|
Telenor
(FORNEBU, NORWAY / SINGAPORE, 03 December 2018) - Seven technology trends stand to reshape how we consume, how we connect and even how we perceive the world around us in 2019, says Telenor Research....
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
December 03, 2018 01:00 ET
|
argenx SE
Regulated information – Inside information Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up to $1.6 billion potentiallyJanssen to pay argenx...
- June 15, 2024 08:57 ET MULTIMEDIA UPDATE -- Rygen Technologies Launches Next-Gen Supply Chain Solution: AI-enabled TMS
- June 14, 2024 21:21 ET Pik'r Range Picking Robot Enhances U.S. Open Experience at Pinehurst